... that, after 4 years of infliximab therapy, the majority of patients had a low level of disease activity and that approximately half of the patients met the criteria for minimal disease activity [18]. ... long -term data is throughnational registry databases, which are primarily maintained toevaluate effectiveness and safety issues [27,28]. Evaluation of the efficacy of long -term therapy shows that, ... reasons for withdrawal (inefficacy, safety,death, or lost to follow- up) ; DAS28 [9,10]; physician's globalVAS, CRP, and HAQ scores prior to infliximab withdrawal; andactual therapy at year...